OmniAb (NASDAQ:OABI – Get Free Report) is one of 39 public companies in the “Commercial physical research” industry, but how does it contrast to its peers? We will compare OmniAb to related companies based on the strength of its risk, analyst recommendations, earnings, profitability, valuation, dividends and institutional ownership.
Valuation and Earnings
This table compares OmniAb and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|OmniAb||$59.08 million||-$22.33 million||-25.35|
|OmniAb Competitors||$1.70 billion||$77.14 million||3.14|
OmniAb’s peers have higher revenue and earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
This is a summary of recent ratings for OmniAb and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
OmniAb presently has a consensus price target of $10.00, suggesting a potential upside of 71.53%. As a group, “Commercial physical research” companies have a potential upside of 12.19%. Given OmniAb’s stronger consensus rating and higher probable upside, equities research analysts plainly believe OmniAb is more favorable than its peers.
Volatility and Risk
OmniAb has a beta of -0.55, suggesting that its share price is 155% less volatile than the S&P 500. Comparatively, OmniAb’s peers have a beta of 5.48, suggesting that their average share price is 448% more volatile than the S&P 500.
This table compares OmniAb and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
OmniAb beats its peers on 7 of the 13 factors compared.
OmniAb Company Profile
OmniAb, Inc., a biotechnology company, engages in the provision of therapeutic antibody discovery technologies in the United States. The company's discovery platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTau, which features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.